Reshaping the Standard of Care for Lymphoma through Cutting-Edge Research


We are committed to improving the cure rate of lymphoma. Our active team approach brings together the top diagnostic hematopathology, diagnostic imaging, and radiation oncology doctors to provide the best comprehensive care for our lymphoma patients.

In May 2015, the lymphoma faculty held a research retreat to discuss and evaluate our major program priorities and scientific directions, and to establish new collaborations to accelerate the development of novel treatment strategies for patients with lymphoma.

Lymphoma Retreat

The Lymphoma Service at their research retreat last spring.

Our top research priorities for the next few years include:

  • Biomarker-driven clinical trials for select patients. We now offer targeted genome sequencing to all consenting patients. This data is increasingly used for optimizing patient selection for specific targeted therapy.
  • Novel immune therapies. We are actively developing several novel immune therapy approaches, including:
    • Engineered CAR T cells
    • Bispecific T cell engagers (BiTEs)
    • Dual-Affinity Re-Targeting (DART) antibody constructs
    • A variety of immune checkpoint (PD-1) inhibitors such as nivolumab and pembrolizumab
    • Other novel naked antibodies and antibody–drug conjugates for rare Burkitt lymphoma and double hit lymphoma
  • Mechanism-based combination therapies. Taking advantage of scientific advances in lymphoma biology, we are designing novel targeted therapy trials that promise enhanced antitumor efficacy. Two examples of combinations of immune therapy–based monoclonal antibodies are:
    • HDAC inhibitor with brentuximab vedotin for patients with relapsed Hodgkin lymphoma
    • BTK inhibitor ibrutinib with the PDA-1 antibody nivolumab for patients with relapsed B cell lymphoma
  • Examining the role of circulating tumor DNA and minimal residual disease on predicting treatment outcome. Using a sequencing-based assay, we are measuring the level of circulating tumor DNA at the end of therapy. This information will inform the design of future clinical trials aimed at eradicating circulating tumor DNA for selected lymphoma types.

To refer patients for participation in our clinical trials, please check our continually updated list of lymphoma clinical trials.

Lymphoma Programatic Priorities